CG Oncology now up 346% from IPO price after latest bladder cancer trial results

CG Oncology went public in January 2024 / Photo: Nasdaq
Shares of biotech CG Oncology rose around 14% to a record close on Monday after its bladder cancer treatment delivered exceptional results in a pivotal clinical trial. The stock is now up 346% from its IPO almost three years ago, and Wall Street sees further upside.
Details
CG Oncology shares jumped around 14% on the Nasdaq on Monday to $84.78 apiece, a record closing price. The rally came after the company released preliminary results from its phase III trial for its bladder cancer treatment, cretostimogene.
The company tested the treatment in patients with non-muscle-invasive bladder cancer, meaning the tumor had yet to grow into the bladder muscle. BCG therapy is used to treat this type of cancer, but it fails in up to 40% of patients. The cancer can recur, and some patients may require bladder removal.
With a median follow-up of 17 months, the trial showed a 68% lower risk of recurrence in patients who received cretostimogene versus the control group. The company reported no treatment-related side effects of grade 3 or higher.
The management expects to complete its initial biologics license application for cretostimogene with the U.S. Food and Drug Administration by the end of March, according to the press release. The initial application will cover a broader group of patients whose cancer did not respond to BCG therapy, a change Barron’s reports is as important to investors as the trial results. The management plans to complete a second application covering additional indications in the second quarter of next year.
What analysts say
Wall Street welcomed the results. The reduction in recurrence risk was “exceptional” and exceeded the 30-40% range the management and investors had been hoping the treatment would surpass, TD Cowen analyst Tyler Van Buren wrote, as reported by BioPharma Dive. “Today’s data clears even the most optimistic bars,” RBC Capital Markets analyst Leonid Timashev told the publication.
“This is a clean beat of the highest bar we set,” Morgan Stanley analyst Sean Laaman said, as quoted by Barron’s. “The data represent the strongest randomized result the segment has seen.” Timashev of RBC estimates that if approved, cretostimogene could generate up to $3.2 billion in peak annual U.S. sales by 2035.
CG Oncology completed its IPO in January 2024, selling 23 million shares at $19 apiece. By Monday’s close, the stock had risen 346% from the offering price. It has 14 “buy” ratings versus one “hold,” according to MarketWatch data. The average target price of $101 per share implies 19% upside from Monday’s close.





